ERBB2 and neoplasm: IL-15-deficient HER2/neu transgenic mice showed an earlier mammary carcinogenesis, with median latency time of tumor onset 4 weeks before that of IL-15-proficient NeuT mice, suggesting a role for IL-15 in tumor immunosurveillance.